Table 1. Clinical characteristics and frequency of genetic aberrations in myeloma IX and myeloma XI trial patients.
|
Myeloma IX trial |
Myeloma XI trial |
P-value | |||
|---|---|---|---|---|---|
| (Total n=869) | Missing information | (Total n=1036) | Missing information | ||
| Clinical characteristics | |||||
| Female | 339 (39.0%) | 398 (38.4%) | 0.81 | ||
| Male | 530 (61.0%) | 638 (61.6%) | 0.81 | ||
| Intensive treatment pathway | 511 (58.8%) | 598 (57.5%) | 0.64 | ||
| Non-intensive treatment pathway | 358 (41.2%) | 438 (42.3%) | 0.64 | ||
| ISS I | 130 (20.7%) | 240 | 225 (23.1%) | 61 | 0.27 |
| ISS II | 253 (40.2%) | 240 | 429 (44.0%) | 61 | 0.15 |
| ISS III | 246 (39.1%) | 240 | 321 (32.9%) | 61 | 0.01 |
| Median age (years) | 65 (range 34–89) | 67 (range 34–88) | 1.0 | ||
| Primary lesions (translocations, HRD) | |||||
| t(4;14) | 104 (11.9%) | 137 (13.2%) | 0.45 | ||
| t(4;14) FGFR3-negative | – | 26 (2.5%) | |||
| t(6;14) | 8 (0.9%) | 1 | 7 (0.7%) | 0.61 | |
| t(11;14) | 129 (14.8%) | 175 (16.9%) | 0.23 | ||
| t(14;16) | 27 (3.1%) | 38 (3.7%) | 0.53 | ||
| t(14;20) | 13 (1.5%) | 13 (1.3%) | 0.69 | ||
| HRD | 499 (58.9%) | 22 | 488 (47.1%) | 3 × 10−7 | |
| Copy number abnormalities | |||||
| Del(1p32) | 87 (10.7%) | 60 | 107 (10.3%) | 0.82 | |
| Gain(1q) or Amp(1q) | 340 (39.1%) | 357 (34.5%) | 0.04 | ||
| Gain(1q) | – | 277(26.7%) | |||
| Amp(1q) | – | 80 (7.7%) | |||
| Gain(6p) or Amp(6p) | – | 122 (12.1%) | 29 | ||
| Gain(6q) or Amp(6q) | – | 69 (6.9%) | 29 | ||
| Del(6q) | – | 157 (15.6%) | 29 | ||
| Del(8p) | – | 164 (16.3%) | 29 | ||
| Gain(8q) | – | 43 (4.3%) | 29 | ||
| Gain(11q25) | – | 418 (41.5%) | 29 | ||
| Del(12p) | – | 78 (7.5%) | |||
| Del(13q) | 389 (45.1%) | 6 | 425 (41.0%) | 0.07 | |
| Del(14q) | – | 144 (13.9%) | |||
| Del(16q) | 153 (17.6%) | 46 | 175 (16.9%) | 0.36 | |
| Del(17p) | 78 (8.9%) | 96 (9.3%) | 0.87 | ||
| Del(22q) | 100 (13.1%) | 103 | 103 (10.2%) | 29 | 0.04 |
| Focal copy number abnormalities/mutations | |||||
| CDKN2C homozygous del | – | 19 (1.8%) | |||
| BIRC2/BIRC3 homozygous del | – | 22 (2.2%) | 29 | ||
| MYC amplification | – | 28 (2.8%) | 29 | ||
| CCND1 focal gain | – | 46 (4.6%) | 29 | ||
| BRAF V600E mutation | – | 36 (3.6%) | 29 | ||
Abbreviations: HRD, hyperdiploid; ISS, International Staging System.